1. Adair J.R. Engineering antibodies for therapy. Immunol. Rev. 1992. 130: 5-40.
2. Andersen, P.S., H. Orum y J. Engberg. One-step cloning of murine Fab gene fragments independent of IgH isotype for phage display libraries. BioTechniques. 1996. 20: 340-2.
3. Ashkenazi, A. y S.M. Chamow. Immunoadhesins as research tools and therapeutic agents. Curr. Opin. Immunol. 1997. 9: 195-200.
4. Behring, E. von S. Kitasato. ünber das zustandekommen der diphtherie-immunitat und der tetanus-immunitat bei thieren. Dtsch. Med. Wochenschr. 1890. 16: 1113-4.
5. Better M., C.P. Chang, R.R. Robinson y A.H. Horwitz. Escherichia coli secretion of an active chimeric antibody fragment. Science. 1988. 240: 1041-3.
6. Bird R.E., K.D. Hardman, J.W. Jacobson, S. Johnson, B.M. Kaufman, S.M. Lee, T. Lee, S.H. Pope, G.S. Riordan y M. Whitlow. Single-chain antigen-binding proteins. Science. 1988. 242: 423-6.
7. Boulianne, G.L., N. Hozumi y M.J. Schulman. Production of functional chimeric mouse/human antibody. Nature. 1984. 312: 643-6.
8. Brennan M., F.P. Davidson y H. Paulus. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science. 1985. 229: 81-3.
9. Brüggemann, M., H.M. Caskey, C. Teale, H. Waldmann, G.T. Williams, M.A. Surani y M.S. Neuberger. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci USA. 1989. 86: 6709-13.
10. Brüggemann, M., G. Winter, H. Waldmann y M.S. Neuberger. The immunogenicity of chimeric antibodies. J. Exp. Med. 1989. 170: 2153-7.
11. Buchwald, M, H. Murialdo, y L. Siminovitch. The morphogenesis of bacteriophage lambda. II. Identification of the principal structural proteins. Virology. 1970. 42: 390-400.
12. Campbell, M.J., A.D. Zelenetz, S. Levy y R. Levy. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol. Immunol. 1992. 29: 193-203.
13. Campbell A.C. Cellular investigations in the diagnosis of lymphoid malignancy. p. 139-74. En Clinical Immunology, a practical approach. H. C. Gooi y H Chapel, Eds. IRL Press 1990.
14. Caton, A.J. y H. Koprowski. Influenza virus hemagglutinin-specific antibodies isolated from a combinatorial expression library are closely related to the immune response of the donor. Proc. Natl. Acad. Sci. USA. 1990. 87: 6450-64.
15. Challita-Eid, P.M., M.L. Penichet, S.U. Shin, T. Poles, N. Mosammaparast, K. Mahmood, D.J. Slamon, S.L. Morrison y J.D. Rosenblatt. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J. Immunol. 1998. 160: 3419-26.
16. Chang, C.N., N.F. Landolfi y C. Queen. Expression of antibody Fab domains on bacteriophage surfaces. Potential use for antibody selection. J. Immunol. 1991. 147: 3610-4.
17. Chotia, C., A.M. Lesk, E. Gherardi, I.M. Tomlinson, G. Walter, J.D. Marks, M.B. Llewelyn y G. Winter. Structural repertoire of the human V_H segments. J. Mol. Biol. 1992. 227: 799-817.
18. Coloma, M.J., A. Hastings, L.A. Wims y S.L. Morrison. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J. Immunol. Meth. 1992. 152: 89-104.
19. Coloma, M.J., J.A. Larrick, M. Ayala y J.Gavilondo. Primer design for the cloning of immunoglobulin heavy-chain leader-variable regions from mouse hybridoma cells using the PCR. Biotechniques.1991. 11: 152-6.
20. Davies, J. y L. Riechmann. Antibody V_H domains as small recognition units. Biotechnology. 1995. 13: 475-479.
21. Deonarain, M.P. y A.A. Epenetos. Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins. Br-J-Cancer. 1998. 77: 537-46.
22. Diamond B.A., D.E. Yelton y M.D. Scharff. Monoclonal antibodies: A new technology for producing serologic reagents. New Eng. J. Med. 1981. 304: 1344-9.
23. Dubel, S. Reconstitution of human pancreatic RNase from two separate fragments fused to different single chain antibody fragments: on the way to binary immunotoxins. Tumor targeting. 1999. 4: 37-46.
24. Earnshaw, W.C. y S.R.Casjens. DNA packaging by the double-stranded DNA bacteriophages. Cell. 1980. 21: 319-31.
25. Ekberg, H., L. Bäckman, G. Tufveson G. Tydén; on behalf of the No 14874 and No 14393 Zenapax Study Groups. Zenapax (Daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. Transp. Proc. 1999. 31: 267-8.
26. Eshhar, Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol. Immunother. 1997. 45: 131-6.
27. Fitzer-Attas, C.J., D.G. Schindler, T. Waks y Z. Eshhar. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J. Immunol. 1998. 160: 145-54.
28. Foote, J. y G. Winter. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 1992. 224: 487-99.
29. Frenken, L.G.J., J.G.M. Hessing, C.A.M.J.J. Van den Hondel y C.T. Verrips. Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms. Res. Immunol. 1998. 149: 589-99.
30. Gavilondo-Cowley, J.V., M.J. Coloma, J. Vazquez, M. Ayala, A. Macias, K.E. Fry y J.W. Larrick. Specific amplification of rearranged immunoglobulin variable region genes from mouse hybridoma cells. Hybridoma. 1990. 9: 407-17.
31. Glassy M.C. Production methods for generating human monoclonal antibodies. Hum. Antibod. Hybridomas. 1993. 4: 154-65.
32. Glennie M.J., H.M. McBride, A.T. Worth y G.T. Stevenson. Preparation and performance of bispecific F(ab’g)2 antibody containing thioether linked Fab’g fragments. J. Immunol. 1987. 139: 2367-75.
33. Gregersen, J., S. Mehdi, H. Gelderblom y G. Zettlmeissl. A CD4: immunoglobulin fusion protein with antiviral effects against HIV. Arch. Virol. 1990. 111: 29-43.
34. Griffiths, A.D., S.C. Williams, O. Hartley, I.M. Tomlinson, P. Waterhouse, W.L. Crosby, R.E. Kontermann, P.T. Jones, N.M. Low, T.J. Allison, T.D. Prospero, H.R. Hoogenboom, A. Nissim, J.P.L. Cox, J.L. Harrison, M. Zaccolo, E. Gherardi y G. Winter. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 1994. 13: 3245-60.
35. Haisma, H.J., M.F. Sernee, E. Hooijberg, R.H. Brakenhoff, I.H. v d Meulen-Muileman, H.M. Pinedo y E. Boven Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood. 1998. 92: 184-90.
36. Hakimi, J., R. Chizzonite, D.R. Luke, P.C. Familletti, P. Bailon, J.A. Kondas, R.S. Pilson, P. Lin, D.V. Weber, C. Spence y col. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol. 1991. 147: 1352-9.
37. Hamers-Casterman, C., T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E.B. Songa, N. Bendahman y R. Hamers. Naturally occurring antibodies devoid of light chains. Nature. 1993. 363: 446-8.
38. Hanes, J. y A. Plückthun. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. USA. 1997. 49: 4937-42.
39. Hayden, M.S., L.K. Gilliland y J.A. Ledbetter. Antibody engineering. Current Opin. Immunol. 1997. 9: 201-12.
40. He, M. M.J. Taussig. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. 1997. 25: 5132-4.
41. Holliger, P., T. Prospero y G. Winter. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl Acad. Sci. 1993. 90: 6444-8.
42. Holliger, P. y G. Winter. Diabodies: small bispecific antibody fragments. Cancer Immunol. Immunother. 1997. 45: 128-30.
43. Holvoet, P. Laroche, H.R. Lijnen, R. Van Cauwenberge, E. Demarsin, E. Brouwers, G. Matthyssens y D. Collen. Characterization of a chimeric plasminogen activator consisting of a single chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single chain urokinase. J. Biol. Chem. 1991. 266: 19717-24.
44. Hoogenboom, H.R., A.P. de Bruine, S.E. Hufton,R.M. Hoet, J.W. Arends, y R.C. Roovers. Antibody phage display technology and its applications. Immunotechnology. 1998. 4:1-20.
45. Hu, S., L. Shively, A Raubitscheck, M. Sherman, L.E. Williams, J.Y. Wong, J.E. Shively y A.M. Wu. Minibody: a novel engineered anti-carcinoembrionic antigen antibody fragment (single-chain Fv-C_H3) which exhibits rapid, high level targeting of xenografts. Cancer Res. 1996. 56: 3055-61.
46. Hudson, P.J. Recombinant antibody fragments. Curr. Opin. Biotechnol. 1998. 9: 395-402.
47. Hurle, M.R. y M. Gross. Protein engineering techniques for antibody humanization. Curr. Opin. Biotechnol. 1994. 5: 428-33.
48. Huse, W.D., L. Sastry, S.A. Iverson, A.S. Kang, M. Alting-Mees, D.R. Burton, S.J. Benkovic y R.A. Lerner. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989. 246: 1275-81.
49. Huston J.S., D Levinson, M. Mudgett-Hunter, M. Tai, J. Novotny, M.N. Margolies, R.J. Ridge, R.E. Bruccoleri, E. Haber, R. Crea y H. Oppermann. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA. Biochemistry. 1988. 85: 5879-83.
50. James, K. y G.T. Bell. Human monoclonal antibody production, current status and future prospects. J. Immunol. Meth. 1987. 100: 5-40.
51. Johnson G.A., T.R. Hansen, K.J. Austin, E.A. Van Kirk y W.J. Murdoch. Baculovirus-insect cell production of bioactive choriogonadotropin-immunoglobulin G heavy-chain fusion proteins in sheep. Biol. Reprod. 1995. 52: 68-73.
52. Jones, P.T., P.H. Dear, J. Foote, M.S. Neuberger y G. Winter. Replacing the complementary determining regions in a human antibody with those from a mouse. Nature. 1986. 321: 522-5.
53. Kang, A.S., C.F. Barbas, K.D. Janda, S.J. Benkovic y R.A. Lerner. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc. Natl. Acad. Sci. U S A. 1991. 88: 4363-4366.
54. Kettleborough, C.A., J. Saldanha, V.J. Heath, C.J. Morrison y M.M. Bendig. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 1991. 4: 773-83.
55. Kobatake, E., H. Sasakura, T. Haruyama, M.L. Laukkanen, K. Keinanen y M.A. Aizawa. Fluoroimmunoassay based on immunoliposomes containing genetically engineered lipid-tagged antibody. Anal. Chem. 1997. 69: 1295-8.
56. Kohler, G. y C. Milstein. Continuous culture of fused cells secreting antibodies of predefined specificity. Nature. 1975. 256: 495-7.
57. Kortt, A.A., M. Lah, G.W. Oddie, L.C. Gruën, J.E. Burns, L.A. Pearce, J.A. Atwell, A.J. McCoy, G.J. Howlett, D.W. Metzger, R.G. Webster y P.J. Hudson. Single chain Fv fragments of anti-neuraminidase antibody NC10 containing five and ten residue linkers form dimers and with zero residue linker a trimer. Protein Eng. 1997. 10: 423-33.
58. Larrick, J.W., L. Danielsson, C.A. Brenner, M. Abrahamson, K.E. Fry y C.A.K. Borrebaeck. Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers y the polymerase chain reaction. Bioch. Bioph. Res. Commun. 1989. 160: 1250-6.
59. Larrick, J.W., L. Danielsson, C.A. Brenner, E.F. Wallace, M. Abrahamson, K.E. Fry y C.A.K. Borrebaeck. Polymerase chain reaction using mixed primers: cloning of human monoclonal antibody variable region genes from single hybridoma cells. Bio/Technology. 1989. 7: 934-8.
60. Larrick, J.W., E.F. Wallace, M.J. Coloma, U. Bruderer, A.B. Lang y K.E. Fry. Therapeutic human antibodies derived from PCR amplification of B-cell variable regions. Immunol. Rev. 1992. 130: 69-85.
61. Leffell M.S. An overview of the immune system: the molecular basis for immune responses Cap. 1. p. 1-45. En Handbook of human immunology. M. S. Leffel, A.D. Donnenberg, y N. R. Rose Eds. CRC Press 1997.
62. Li, E., A. Pedraza, M. Bestagno, S. Mancardi, R. Sanchez y O. Burrone. Mammalian cell expression of dimeric small immune proteins. Protein Eng. 1997. 10: 731-6.
63. Lobuglio, A.F., R.H. Wheeler, J. Trang, A. Haynes, K. Rogers, E.B. Harvey, L. Sun, J. Ghrayeb y M.B. Khazaeli. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA. 1989. 86: 4220-4.
64. Luo, D., N. Mah, M. Krantz, D. Wishart, F. Jacobs, and L. Martin. 1997. High level secretion of single-chain antibody in Pichia expression system. Biotechnol. Techn. 11: 759-61.
65. Ma, J.K.C. y M.B. Hein. Antibody production and engineering in plants. Ann. N. Y. Acad. Sci. 1996. 792: 72-81.
66. Marks, J.D., M. Tristem, A. Karpas y G. Winter. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur. J. Immunol. 1991. 21: 985-91.
67. Martin F., C. Toniatti, A.L. Salvati, S. Venturini, G. Ciliberto, R. Cortese y M. Sollazzo. The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6. EMBO J. 1994. 13: 5303-9.
68. McCafferty, J., A.D. Griffiths, G. Winter y D.J. Chiswell. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990. 348: 552-4.
69. McGrath, J.P., X. Cao, A. Schutz, P. Lynch, T. Ebendal, M.J. Coloma, S.L. Morrison y S.D. Putney. Bifunctional fusion between nerve growth factor and a transferrin receptor antibody. J. Neurosci. Res. 1997. 47: 123-33.
70. Model, P. y M. Russel. Filamentous bacteriophage. En The bacteriophages, vol.2. Valdner R. ed. Plenum Press. 1988.
71. Montaño R.F. y E.L. Romano. Anticuerpos monoclonales y su aplicación en hematología. Interciencia. 1995. 20: 194-203.
72. Morrison, S.L. In vitro antibodies: strategies for production and application. Ann. Rev. Immunol. 1992. 10: 239-65.
73. Morrison S.L., M.J. Johnson, L.A. Herzenberg y V.T. Oi. Chimeric human antibody molecules: mouse antigen binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA. 1984. 81: 6851-5.
74. Morrison, S.L. y V.T. Oi. Genetically engineered antibody molecules. Adv. Immunol. 1989. 44: 65-92.
75. Mouser J.F. y J.S. Hyams. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin. Ther. 1999. 21: 932-42.
76. Mullinax, R.L., E.A. Gross, J.R. Amberg, B.N. Hay, H.H. Hogrefe, M.M. Kubitz, A. Greeener, M. Alting-Mees, D. Ardourel, J.M. Short, J.A. Sorge y B. Shopes. Identification of human antibody fragment clones specific for Tetanus Toxoid in a bacteriophage l immunoexpression library. Proc. Natl. Acad. Sci. USA 1990. 87: 8095-9.
77. Nguyen, V.K., R. Hamers, L. Wyns y S. Muyldermans. Loss of splice consensus signal is responsible for the removal of the entire C_H1 domain of the functional camel IgG2A heavy-chain antibodies. Mol. Immunol. 1999. 36: 515-24.
78. Oritani, K. Kanakura, K. Aoyama, T. Yokota, N.G. Copeland, D.J. Gilbert, N.A. Jenkins, Y. Tomiyama. Matsuzawa y P.W. Kincade. Matrix glycoprotein SC1/ECM2 augments B lymphopoiesis. Blood. 1997. 90: 3404-13.
79. Onrust, S.V. y L.R. Wiseman. Basiliximab. Drugs. 1999. 57: 207-13.
80. Orlandi, R., D.H. Güssow, P.T. Jones y G. Winter. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA. 1989. 86: 3833-7.
81. Padlan, E.A. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol. 1991. 28: 489-98.
82. Padlan E.A. Anatomy of the antibody molecule. Mol. Immunol. 1994. 31:169-217.
83. Penichet, M.L., E.T. Harvill y S.L. Morrison. An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity. J. Interferon. Cytokine Res. 1998. 18: 597-607.
84. Plückthun A., A. Krebber, C. Krebber, U. Horn, U. Knüpfer, R. Wenderoth, L. Nieba, K. Proba y D. Riesenberg. Producing antibodies in Escherichia coli: from PCR to fermentation. p. 203-52. En Antibody Engineering: a practical approach. H. Hoogenboom, J. McCafferty y D. Chiswell Eds. Oxford. IRL Press. 1996.
85. Portolano, S., P. Seto, G.D. Chazenbalk, Y. Nagayama, S.M. Mclachlan y B. Rapoport. A human Fab fragment specific for Thyroid Peroxidase generated by cloning Thyroid lymphocyte-derived immunoglobulin genes in a bacteriophage l library. Biochem. Byophys. Res. Commun. 1991. 179: 372-6.
86. Presta, L. Antibody engineering. Curr. Opin. Biotechnol. 1992. 3: 394-8.
87. Queen, C., W.P. Schneider, H.E. Selick, P.W. Paine, N.F. Landolfi, J.F. Duncan, N.M. Avdalovic, M. Levitt, R.P. Hunghans y T.A. Waldman. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA. 1989. 86: 10029-33.
88. Rader, C. y C.F. Barbas III. Phage display of combinatorial antibody libraries. Curr. Opin. Biotechnol. 1997. 8: 503-8.
89. Rasched, I. y E. Overer. Ff coliphages: structural and functional relationships. Microb. Rev. 1986. 50: 401-27.
90. Ridgway, J.B.B., L.G. Presta y P. Carter: ‘Knobs-into-holes’ engineering of antibody C_H3 domains for heavy chain heterodimerization. Protein Eng. 1996. 9: 617-21.
91. Rode, H.J., M. Little, P. Fuchs, H. Dorsam, H. Schooltink, C. de Ines, S. Dubel y F. Breiling. Cell surface display of a single-chain antibody for attaching polypeptides. BioTechniques. 1996. 21: 652-9.
92. Russel, M. Filamentous phage assembly. Mol. Microbiol. 1991. 5: 1607-13.
93. Sastry, L., M. Alting-Mees, W.D. Huse, J.M. Short, J.A. Sorge, B.N. Hay, K.D. Janda, S.J. Benkovic y R.A. Lerner. Cloning of the immunological repertoire in Escherichia coli for generation of monoclonal catalytic antibodies: construction of a heavy chain variable region-specific cDNA library. Proc. Natl. Acad. Sci. USA. 1989. 86: 5728-32.
94. Saul, F.A. y R.J. Poljak. Structural patterns at residue positions 9, 18, 67 and 82 in the VH framework regions of human and murine immunoglobulins. J. Mol. Biol. 1993. 230: 15-20.
95. Sblattero D. y A. Bradbury. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology.1998. 3: 271-8.
96. Shak, S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 1999. 26: 71-7.
97. Skerra, A. y A. Pluckthun. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science. 1988. 240: 1038-41.
98. Smith, G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the surface of the virion. Science. 1985. 228: 1315-17.
99. Smith, G.P. Patch engineering: a general approach for creating proteins that have new binding activities. Trends Biochem. Sci. 1998. 23: 457-60.
100. Smith, R.I.F. y S.L. Morrison. Recombinant polymeric IgG: an approach to engineering more potent antibodies. Bio/technology. 1994. 12: 683-88.
101. Taylor, L.D., C.E. Carmack, S.R. Schramm, R. Mashayekh, K.M. Higgins, C.C. Kuo, C. Woodhouse, R.M. Kay y N. Lonberg. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res. 1992. 20: 6287-95.
102. Tramontano A, E. Bianchi, S. Venturini, F. Martin, A. Pessi, M. Sollazzo M The making of the minibody: an engineered beta-protein for the display of conformationally constrained peptides. J. Mol. Recognit. 1994. 7: 9-24.
103. Trill, J.J., A.R. Shatzman y S. Ganguly. Production of monoclonal antibodies in COS and CHO cells. Curr. Opin. Biotechnol. 1995. 6: 553-60.
104. Vallera, D.A., A. Panoskaltsis-Mortari y B.R. Blazar. Renal dysfunction accounts for the dose limiting toxicity of DT390anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin. Protein-Eng. 1997. 10: 1071-6.
105. Vaughan, T.J., A.J. Williams, K. Pritchard, J.K. Osbourn, A.R. Pope, J.C. Earnshaw, J. McCafferty, R.A. Hodits, J. Wilton y K.S. Johnson. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 1996. 14: 309-14.
106. Verhoeyen M, C. Milstein y G. Winter. Reshaping human antibodies: grafting an antilysozyme activity. Science, 1988. 230: 1534-6.
107. Waldmann, T.A. Monoclonal antibodies in diagnosis and therapy. Science. 1991. 252: 1657-62.
108. Wang, L., M.Z. Radic, D. Siegel, T. Chang, J. Bracy y U. Galili. Cloning of anti-Gal Fabs from combinatorial phage display libraries: structural analysis and comparison of Fab expression in pComb3H and pComb8 phage. Mol. Immunol. 1997. 34: 609-18.
109. Waterhouse, P., A.D. Griffiths, K.S. Johnson y G. Winter. Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires. Nucleic Acids Res. 1993. 21: 2265-6.
110. Weiner, L.M., R.K. Alpaugh y M. von Mehren. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins. Cancer Immunol. Immunother. 1997. 45: 190-2.
111. Welschof, M., P. Terness, F. Kolbinger, M. Zewe, S. Dübel, H. Dörsam, C. Hain, M. Finger, M. Jung, G. Moldenhauer, N. Hayashi, M. Little y G. Opelz. Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes. J. Immunol. Meth. 1995. 179: 203-14.
112. Williamson, R.A., M.A.A. Persson y D.R. Burton. Expression of a human monoclonal anti-(rhesus D) Fab fragment in Escherichia coli with the use of bacteriophage l vectors. Biochem J. 1991. 277: 561-3.
113. Williamson, R.A., R. Burioni, P.P. Sanna, L.J. Partridge, C.F. Barbas III y D.R. Burton. Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc. Natl. Acad. Sci. USA. 1993. 90: 4141-5.
114. Winkelstein A. y A.D. Donnenberg. Clinical applications of flow cytometry. Cap. 11, p.381-476. En Handbook of human immunology. M. S. Leffel, A.D. Donnenberg N. R. Rose Eds. CRC Press 1997.
115. Winter, G. y W.J. Harris. Humanized antibodies. Immunol. Today 1993. 14: 243-6.
116. Wright, A., Seung-Uon Shin y S.L. Morrison. Genetically engineered antibodies: progress and prospects. Crit. Rev. Immunol. 1992. 12: 125-68.
117. Young, M.W., H. Meade, J.M. Curling, C.A. Ziomek y M. Harvey. Production of recombinant antibodies in the milk of transgenic animals. Res. Immunol. 1998. 149: 609-10.
118. Zhu, Z., G.D. Lewis y P Carter. Engineering high affinity humanized anti-p185^HER2/anti-CD3 bispecific F(ab’)₂ for efficient lysis of p185^HER2 overexpressing tumor cells. Int. J. Cancer. 1995. 62: 319-24.

Sitios Web

• (1w) http://www.nobel.se/prize
• (2w) http://www.craigmedical.com/marijuan.htm
• (3w) http://www.vancouverbiotech.com/vbl98/diagnostic.htm
• (4w) http://www.advimmuno.com
• (5w) http://www.vancouverbiotech.com/vbl98/psa.htm
• (6w) http://www.dbc-labs.com/3_eiasy.htm#cea
• (7w) http://www.biodesign.com/new/hepatitis.asp
• (8w) http://www.xtlbio.com/home.html
• (9w) http://www.abgenix.com/abgenix_solution.htm